ArticleOpen forum infectious diseases2026
PrEParing for Long-acting Technologies: A Multistate Analysis of PrEP Persistence and HIV and STI Lab Coverage Among Oral PrEP Initiators in St. Louis, Missouri (2014-2021).
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Engagement in pre-exposure prophylaxis (PrEP) care and routine screening for HIV and sexually transmitted infections (STIs) is critical to realizing the full benefits of this HIV prevention strategy. Methods: We enrolled a cohort of individuals seeking PrEP services in two clinics in Missouri, an Ending the HIV Epidemic priority state, from June 2014 to November 2021. We used electronic health record and survey data to explore outcomes in the 2 years following linkage to care using multistate methods. We assessed transitions between eight mutually exclusive care states differentiated by receipt of a prescription, lab coverage status, and retention. We describe outcomes in the population overall and distinct sociodemographic subgroups. Results: A total of 470 individuals were included (90.3% male; median age 29 (IQR, 25-36); 52.9% White, non-Hispanic) and contributed 879.5 person-years of follow-up. One week following linkage to care, 86.8% (95% CI: 83.6-90.0) of participants had a PrEP prescription. At month 6, 35.2% (95% CI: 30.7-39.7) were in care but had a lapse in HIV/STI screening, at month 12, 48.3% (95% CI: 43.7-53.1) were disengaged from care. Of those who disengaged, 28.3% (95% CI: 23.9-32.7) were re-engaged 6 months later. Females and uninsured individuals were the most likely to disengage during the first year of follow-up. Conclusions: Lapses in clinic visits and lab screening are common among PrEP users in Missouri and most who disengage do not return. Females, uninsured individuals, and other marginalized groups may be particularly susceptible to poor persistence suggesting targeted interventions are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.